<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596164</url>
  </required_header>
  <id_info>
    <org_study_id>SHP633-307</org_study_id>
    <nct_id>NCT03596164</nct_id>
  </id_info>
  <brief_title>An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004</brief_title>
  <official_title>An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the long-term safety and efficacy of
      teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent
      SBS (short bowel syndrome) who completed SHP633-306 or who were in the extension phase of the
      TED-C14-004 (NCT02340819) study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Demonstrate at least 20 Percent (%) Reduction From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Number of participants who demonstrate at least 20% reduction in PN/IV volume will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Absolute change in PN/IV volume will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Relative change in PN/IV volume will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Completely Wean off Parenteral Nutrition Intravenous (PN/IV) Support</measure>
    <time_frame>Baseline, End of the study (3 years)</time_frame>
    <description>Number of participants who completely wean off PN/IV support will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Days per Week of Parenteral Nutrition Intravenous (PN/IV) Support</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change in days per week of PN/IV will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Citrulline</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change in plasma citrulline will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From start of study treatment up to End of study (3 years)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change in blood pressure will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change in pulse rate will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change in body temperature will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change from baseline in hemoglobin will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change from baseline in hematocrit will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Blood Urea Nitrogen</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change from baseline in serum blood urea nitrogen will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Creatinine</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change from baseline in creatinine will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urine Sodium</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Change from baseline in urine sodium will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Report Positive Specific Antibodies to Teduglutide</measure>
    <time_frame>Baseline, every six months until End of study (3 years)</time_frame>
    <description>Number of participants classified as having positive specific antibodies to teduglutide will be used to summarize the presence of antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in 48-Hour Urine Output</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Urine output will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Changes in body weight will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI)</measure>
    <time_frame>Baseline to each study visit until End of study (3 years)</time_frame>
    <description>Changes in body mass index will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Colonoscopy/Sigmoidoscopy Results</measure>
    <time_frame>Baseline, Month 24, End of the study (3 years)</time_frame>
    <description>Number of participants who have normal, abnormal but clinically insignificant, and abnormal clinically significant results will be assessed.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Syringe</intervention_name>
    <description>Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle</intervention_name>
    <description>Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vial Adapter for Device</intervention_name>
    <description>Vial adapter for device is approved for use in Japan by PMDA.</description>
    <arm_group_label>Teduglutide 0.05 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants who meet all of the following criteria will be enrolled in this study:

          1. Ability to voluntarily provide written, signed, and informed consent to participate in
             the study.

          2. Completion of the SHP633-306 study or participation in TED-C14-004 (NCT02340819) Stage
             3 or Stage 4.

          3. Females of childbearing potential must agree to comply with the contraceptive
             requirements of the protocol.

          4. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

        Exclusion Criteria:

        There are no exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi-Ken</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen's Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, â€¦).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

